Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Richard Thomas Penson, M.B.,B.S.

Co-Author

This page shows the publications co-authored by Richard Penson and Hang Lee.
Connection Strength

1.213
  1. The Feasibility and Effects of Acupuncture on Quality of Life Scores During Chemotherapy in Ovarian Cancer: Results from a Pilot, Randomized Sham-Controlled Trial. Med Acupunct. 2012 12; 24(4):233-240.
    View in: PubMed
    Score: 0.134
  2. Phase II trial of GM-CSF in women with asymptomatic recurrent müllerian tumors. Gynecol Oncol. 2010 Feb; 116(2):168-72.
    View in: PubMed
    Score: 0.109
  3. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol. 2010 Jan 01; 28(1):154-9.
    View in: PubMed
    Score: 0.109
  4. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol. 2009 Nov 20; 27(33):5601-6.
    View in: PubMed
    Score: 0.108
  5. Acupuncture for chemotherapy-induced neutropenia in patients with gynecologic malignancies: a pilot randomized, sham-controlled clinical trial. J Altern Complement Med. 2009 Jul; 15(7):745-53.
    View in: PubMed
    Score: 0.106
  6. Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian tumors. Gynecol Oncol. 2009 Feb; 112(2):394-9.
    View in: PubMed
    Score: 0.102
  7. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2008 Dec 10; 26(35):5761-6.
    View in: PubMed
    Score: 0.101
  8. Long-term adjustment of early-stage ovarian cancer survivors. Int J Gynecol Cancer. 2008 Nov-Dec; 18(6):1183-93.
    View in: PubMed
    Score: 0.096
  9. Attitudes to chemotherapy in patients with ovarian cancer. Gynecol Oncol. 2004 Aug; 94(2):427-35.
    View in: PubMed
    Score: 0.075
  10. Phase I trial of escalating doses of topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with müllerian malignancies. Gynecol Oncol. 2004 Jun; 93(3):702-7.
    View in: PubMed
    Score: 0.074
  11. Clinical trial participation and aggressive care at the end of life in patients with ovarian cancer. Int J Gynecol Cancer. 2020 02; 30(2):201-206.
    View in: PubMed
    Score: 0.055
  12. Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin. Gynecol Oncol. 2019 05; 153(2):223-229.
    View in: PubMed
    Score: 0.052
  13. Long-term adjustment of survivors of ovarian cancer treated for advanced-stage disease. J Psychosoc Oncol. 2010; 28(5):451-69.
    View in: PubMed
    Score: 0.027
  14. Comparison of the quality of life of early and advanced stage ovarian cancer survivors. Gynecol Oncol. 2009 Aug; 114(2):353-9.
    View in: PubMed
    Score: 0.026
  15. Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: the modified triple doublet regimen. Gynecol Oncol. 2006 Nov; 103(2):575-80.
    View in: PubMed
    Score: 0.021
  16. Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Müllerian tumors. Gynecol Oncol. 2003 Sep; 90(3):610-8.
    View in: PubMed
    Score: 0.018
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.